AR055346A1 - Composiciones farmaceuticas de glp -1 - Google Patents

Composiciones farmaceuticas de glp -1

Info

Publication number
AR055346A1
AR055346A1 ARP060102840A ARP060102840A AR055346A1 AR 055346 A1 AR055346 A1 AR 055346A1 AR P060102840 A ARP060102840 A AR P060102840A AR P060102840 A ARP060102840 A AR P060102840A AR 055346 A1 AR055346 A1 AR 055346A1
Authority
AR
Argentina
Prior art keywords
subject
formula
analogs
glp
cells
Prior art date
Application number
ARP060102840A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR055346A1 publication Critical patent/AR055346A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Análogos peptídicos de péptido-1 tipo glucagon, sus sales farmacéuticamente aceptables, a método para la utilizacion de tales análogos para tratar mamíferos y a composiciones farmacéuticas utiles para tal fin que comprenden dichos análogos. Reivindicacion 1: Una composicion farmacéutica que comprende un análogo de acuerdo con la formula: [Aib8,35]hGLP-1(7-36)NH2; junto con zinc y un portador o diluyente farmacéuticamente aceptable. Reivindicacion 37: Un método para activar un efecto agonista de GLP-1, comprendiendo dicho método poner en contacto un receptor del ligando GLP-1(7-36)NH2 con el compuesto de acuerdo con la formula (1), dicho compuesto de acuerdo con la formula (1) es proporcionado a dicho receptor, directa a indirectamente, por medio de una composicion de acuerdo con la reivindicacion 1. Reivindicacion 44: Un método para convertir células madre/progenitoras hepáticas en células pancreáticas funcionales, para prevenir el deterioro de células beta y para estimular la proliferacion de células beta, para suprimir los niveles sanguíneos plasmáticos de norepinefrina, para inducir una respuesta inotropica y para aumentar la contractilidad cardíaca, para mejorar la nutricion por medio de una ruta no alimentaría, para el pretratamiento de un sujeto para sufrir un procedimiento endoscopico, y para modular los niveles de triglicéridos, en un sujeto que lo necesita, comprendiendo dicho método administrar a dicho sujeto una composicion farmacéutica de acuerdo con la reivindicacion 1.
ARP060102840A 2005-06-30 2006-06-30 Composiciones farmaceuticas de glp -1 AR055346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69614205P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
AR055346A1 true AR055346A1 (es) 2007-08-22

Family

ID=37605098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102840A AR055346A1 (es) 2005-06-30 2006-06-30 Composiciones farmaceuticas de glp -1

Country Status (13)

Country Link
US (2) US8236759B2 (es)
EP (2) EP2441460A1 (es)
KR (1) KR20080028981A (es)
CN (1) CN101258163B (es)
AR (1) AR055346A1 (es)
AU (1) AU2006265814B2 (es)
CA (1) CA2617859A1 (es)
EA (1) EA012287B1 (es)
MX (1) MX2008001468A (es)
NO (1) NO20080552L (es)
NZ (1) NZ565535A (es)
TW (1) TWI364292B (es)
WO (1) WO2007005738A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008082656A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CL2008001671A1 (es) * 2007-06-08 2009-07-17 Janssen Pharmaceutica Nv Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
EP2296659B1 (en) 2008-06-05 2016-12-21 Janssen Pharmaceutica, N.V. Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
EP2216042A1 (en) * 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
CN106999553B (zh) * 2014-05-07 2021-11-26 诺和诺德股份有限公司 使用glp-1和抗-il-21对1型糖尿病的治疗

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Ltd Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69904701T2 (de) 1998-03-20 2003-11-06 Takeda Chemical Industries Ltd Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
ES2227115T5 (es) 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
CA2402733A1 (en) 2000-03-14 2001-09-20 Burkhard Goke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
KR100518046B1 (ko) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002016430A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University Peptide with effects on cerebral health
ATE470448T1 (de) 2000-10-20 2010-06-15 Amylin Pharmaceuticals Inc Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
CN1501809B (zh) 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
SK1432004A3 (sk) 2001-10-01 2005-03-04 Eli Lilly And Company Liečivo na znižovanie mortality a morbidity súvisiacich s kritickými ochoreniami
JP2005506074A (ja) 2001-10-18 2005-03-03 イクシオン・バイオテクノロジー・インコーポレーテッド 肝臓の幹細胞および前駆細胞の膵臓機能細胞への転換
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
JP2007514752A (ja) 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EP2409707B8 (en) * 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu
JP5000493B2 (ja) * 2004-05-20 2012-08-15 ディアメディカ インコーポレイテッド インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット

Also Published As

Publication number Publication date
NZ565535A (en) 2011-03-31
MX2008001468A (es) 2008-04-07
EP2441460A1 (en) 2012-04-18
KR20080028981A (ko) 2008-04-02
US20120277151A1 (en) 2012-11-01
WO2007005738A3 (en) 2007-09-13
NO20080552L (no) 2008-03-27
TWI364292B (en) 2012-05-21
CA2617859A1 (en) 2007-01-11
TW200740456A (en) 2007-11-01
EA200800181A1 (ru) 2008-06-30
AU2006265814B2 (en) 2012-05-10
CN101258163A (zh) 2008-09-03
US8236759B2 (en) 2012-08-07
AU2006265814A1 (en) 2007-01-11
WO2007005738A2 (en) 2007-01-11
EP1904525A4 (en) 2009-10-21
EA012287B1 (ru) 2009-08-28
US20070021339A1 (en) 2007-01-25
CN101258163B (zh) 2013-08-21
EP1904525A2 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
AR055346A1 (es) Composiciones farmaceuticas de glp -1
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
PE20160683A1 (es) Analogos de glucagon acilados
PE20120914A1 (es) Compuestos glucagon activo de receptor de gip
DK1902026T3 (da) Tetrahydrocarbazol-derivater, der kan anvendes som androgen-receptor-modulatorer (SARM)
DOP2012000244A (es) Nuevos péptidos y métodos para su preparación y uso
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
PE20070022A1 (es) Compuestos derivados de pirrolopiridina como inhibidores de dipeptidil peptidasa iv
AR085086A1 (es) Uso de analogos de glucagon acilados
SV2009003146A (es) Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct)
CR20120062A (es) Terapia combinada para el tratamiento de la diabetes
DK1891038T3 (da) Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
PE20091425A1 (es) Derivados de aminotiazol
GT201300001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
AR111199A1 (es) Compuesto aromático agonista de gpr40
PA8803201A1 (es) Derivados acidos de cicloalquilamino
CO6400144A2 (es) Derivados aminoéster de alcaloides y composición medicinal de los mismos
CL2008003927A1 (es) Compuestos derivados de imidazo[1,2-a]piridina-2-heterociclil-metanona, moduladores de los receptores nucleares nurr1; compuestos intermediarios; composicion farmaceutica; medicamento; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, osteoporosis, cancer, entre otras.
ECSP11011099A (es) Péptidos agonistas de crhr2 y usos de estos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal